Zum Inhalt springenZur Suche springen

Program 2021



Prof. Dr. Holger Gohlke

Insitute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Düsseldorf

Welcome and Introduction

13:10 – 14:00

Dr. Simone Moser

Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich

Phyllobilins - Chlorophyll breakdown as source of bioactive compounds

14:00 – 14:30

Marco Kruppa

Insitute of Organic Chemistry, Heinrich-Heine-University Düsseldorf

Diversity-oriented synthesis of symmetrically and unsymmetrically substituted Alocasin A derivatives against therapy resistant bacteria

14:30 – 15:00

Laura Schmitt

Institute of Molecular Biology I, Heinrich-Heine-University, Düsseldorf

The impact of novel meriolin derivatives on apoptosis and cell cycle progression in leukemia cells

15:00 – 15:15

Short Break

15:15 – 15:55

Dr. Susanne Roehrig

Bayer AG Pharmaceuticals

Discovery and development of the novel antithrombotic agent rivaroxaban, an orally active, direct factor Xa inhibitor

15:55 – 16:45

Prof. Dr. Anna K. H. Hirsch

Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS),

Helmholtz Centre for Infection Research &

Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany

Addressing unusual anti-infective targets

16:45 – 17:00

Short Break

17:00 – 17:50

Prof. Dr. Jon Clardy

Blavatnik Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA

Chasing molecules and mechanisms in the human gut microbiome


Holger Gohlke

Closing Remarks